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บทคัดยอ 
วัตถุประสงค: เพื่อเปรียบเทียบผลระยะสั้นตอคุณภาพชีวิตที่สัมพันธกับ
ภาวะน้ําลายแหงในผูปวยมะเร็งศีรษะและลําคอที่ไดรับรังสีรักษา ระหวาง
ผลิตภัณฑน้ําลายเทียม 2 ชนิด คือ 1) ชนิดที่มีคารบอกซีเมทิลเซลลูโลส 
(CMC) กับ 2) ชนิดที่มีเอนไซม (Enzyme) วิธีการศึกษา: ตัวอยางเปน
ผูปวยมะเร็งศีรษะและลําคอ 50 คน ที่ประเมินตนวามีคะแนนภาวะน้ําลาย
แหงโดยมีvisual analog scale score ≥ 50 มม. แบงเปน 2 กลุม (1:1) 
โดยการสุม แลวใชผลิตภัณฑน้ําลายเทียมชนิด CMC หรือ Enzyme นาน 
2 สัปดาห ประเมินคุณภาพชีวิตที่สัมพันธกับภาวะน้ําลายแหงกอนและหลัง
ใชน้ําลายเทียมดวยแบบประเมินดวยตนเองทดสอบความตางของคุณภาพ
ชีวิตที่สัมพันธกับภาวะภาวะน้ําลายแหงระหวางกลุมโดยพจิารณาความตาง
กอนการทดลองรวมดวย โดยสถิติ ANCOVA และทดสอบความตางของตัว
แปรไมตอเนื่องโดย chi-square ที่ระดับนัยสําคัญทางสถิติ 0.05 ผล
การศึกษา: เม่ือครบ 2 สัปดาห พบวาคาเฉลี่ยความรุนแรงของภาวะ
น้ําลายแหงในกลุม CMC และกลุม Enzyme เทากับ 50.1 และ 52.1 มม.
ตามลําดับ (P–value = 0.87) สัดสวนตัวอยางที่ระบุวาตอบสนองหรือมี
คุณภาพชีวิตเพิ่มข้ึนอยางมากเมื่อเทียบกับคาตั้งตนของคะแนนทั้งในมิติ
ดานหนาที่ทางกายและความเจ็บปวด/ไมสบาย รวมถึงความยอมรับทาง
คลินิกดานอื่น ๆ ของทั้งสองกลุมไมตางกัน สรุป: ไมพบความแตกตางทาง
สถิติระหวางการใชน้ําลายเทียมที่มีคารบอกซีเมทิลเซลลูโลสกับที่มีเอนไซม
เปนสวนประกอบตอคุณภาพชีวิตที่สัมพันธกับภาวะน้ําลายแหง ในผูปวย
มะเร็งศีรษะและลําคอที่มีภาวะน้ําลายแหง  
คําสําคัญ: ภาวะน้ําลายแหง, รังสี, คารบอกซีเมทิลเซลลูโลส, สารทดแทน
น้ําลาย, คุณภาพชีวิต 
 
Abstract 
Objective: To compare short-term effects of two commercially 
available saliva substitutes, carboxymethylcellulose (CMC) based 
preparation and enzyme-containing saliva substitute, on xerostomia-
related quality of life (QoL) in postradiation head and neck cancer 
(HNC) patients. Method: Fifty HNC patients with xerostomia whose 
self-rated xerostmia VAS score of ≥ 50 mm were blinded and 
randomly assigned (1:1) to receive either CMC based (CMC group) 
or enzyme-containing saliva substitute (ENZ group), each for 14 
days. A xerostomia questionnaire was used to evaluate self-rated 
xerostomia-related QoL. ANCOVA was used to compare response 
differences adjusting for baseline differences. Chi-square statistics 
were used to test categorical parameters between groups. P-value of 
< 0.05 was considered significant. Results: After treatment, mean 
VAS scores of xerostomia severity in CMC and ENZ groups were 
50.1 and 52.1 mm, respectively (P–value = 0.87). Proportions of 
patients reporting a “response” or “major improvement” from baseline 
in each of all individual QoL questions, and in other clinical 
acceptance were comparable between groups. Conclusion: No 
significant difference on xerostomia-related QoL was observed 
between CMC based and enzyme-containing saliva substitute usage 
in HNC patients with xerostomia.  
Keywords: xerostomia, radiation, carboxymethylcellulose, saliva 
substitute, quality of life 
   
Introduction
Radiation therapy (RT) is a very effective treatment of 
head and neck cancer (HNC); however, it generally causes 
acute and long-term unwanted effects. One of the most 
common complications is xerostomia, a subjective complaint 
of dry mouth due to a lack of saliva. Xerostomia can cause 
difficulty in speech, chewing and swallowing. It also causes 
altered taste and burning sensation, affects the use of oral 
prosthesis, and increases risk of dental caries and oral 
infections.1,2  These problems may lead to severe and long 
term oral diseases, and impaired quality of life (QoL) of 
potentially cured cancer patients.3,4  
Since it is not possible to correct the cause, treatment of 
radiation related xerostomia focuses on relieving symptoms. 
Wetting the oral tissue alleviates the symptoms of 
xerostomia. There are various preparations of saliva 
substitutes developed and available for selection. Among 
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commercial saliva substitute products, carboxymethylcell- 
ulose (CMC)-based saliva substitutes have been used and 
evaluated extensively.5-7 CMC however does not completely 
resemble many properties of saliva such as viscosity, 
wetting, sheeting, stringing, and elasticity.5 It also does not 
contain specific antibacterial components and enzymes 
found in human saliva.  
Various kinds of saliva substitute have been developed 
to help maintain a healthy balance in the mouth and 
encourage healthy oral flora. These new preparations 
contain either immunologic components such as 
immunoglobulins or enzymatic components such as 
lysozyme, lactoferrin, and lactoperioxidase.5 It has been 
reported that the soothing effects of enzyme-engineered 
saliva substitutes are superior to the effects of CMC based 
saliva substitutes.5  
Aside from better soothing effect, enzyme-containing 
saliva substitutes had no effect on colonization of candida 
species and cariogenic oral microflora and it did not promote 
infection in different groups of patients.5,8,9 Nagy et al10 also 
found that enzyme-engineered products assist in controlling 
oral microbial flora. Furthermore, there were also researches 
indicating that enzyme-engineered saliva substitute products 
alleviate the symptoms of radiation-induced xerostomia.11.12 
Self-evaluated QoL represents the individual’s sense of well-
being which is potentially affected by an illness and its 
treatment.13 Performance of contemporary saliva substitutes 
has been summarized.14 Previous studies reported effects of 
saliva substitute in treatment of radiation-induced xerostomia 
evaluated by either laboratory results or dentist-assessment 
of clinical performance of patients. Whether enzyme-
containing saliva substitute or CMC-based saliva substitute 
is better in improving patient’s self-assessed QoL has not 
been tested.  
The purpose of this present study was to compare the 
clinical effects of commercially available carboxymethyl-
cellulose based saliva substitute with enzyme-containing 
saliva substitute by using the comprehensive questionnaire 
related to the Xerostomia-related Quality of Life Scale 
(XeQoLS). This would guide the selection of the 
commercially available saliva substitutes for alleviating the 
distress symptoms of xerostomia in HNC patients.  
 
 
 
Materials and Method 
Patient selection 
This study was a prospective, open-label, comparative 
study in which two saliva substitute preparations were 
randomly assigned to patients previously treated with RT for 
HNC and came in for their regular follow-up visits at the 
multidisciplinary outpatient clinic at King Chulalongkorn 
Memorial Hospital. The Institutional Review Board of the 
Medical School of Chulalongkorn University, Thailand 
granted approval for this study on August 27, 2009 (IRB 
Number 200.1/52). The examiner explained the study to 
each participant who read, agreed, and provided written 
informed consent before enrollment.  
Patients eligible to participate in this study were 18 years 
or older and had subjective complaints of xerostomia with 
self-evaluated xerostomia VAS score of ≥ 50mm. All patients 
had completed either parotid-sparing radiation technique or 
conventional radiotherapy of 66-70cGy/33-35F with the fields 
of radiation encompassing the major and minor salivary 
glands for at least 1 month before enrollment into this study. 
Those who received bilateral Intensity Modulated RT (IMRT) 
were included if they completed the RT within 12 months 
before enrollment. Patients who received unilateral or 
bilateral conventional RT were also included. All patients 
took nutrition orally and had at least one tenth of their 
natural teeth remaining. Patients with evidence of a 
persisting or recurring malignant disease or terminal cancer, 
and those with Sj⍥gren’s syndrome or with medical 
conditions that cause xerostomia were not included.  
The VAS xerostomia scores were translated into a four-
grade xerostomia scale4,15,16, where grade 0 = VAS score of 
24 or less (no xerostomia), grade 1 = VAS score between 25 
and 49 (now and then, partially dry), grade 2 = VAS score 
between 50 and 74 (always, partially dry), and grade 3 = 
VAS score between 75 and 100 (completely dry, disturbing).  
Patients were instructed to refrain from using any other 
treatment for xerostomia (e.g., saliva stimulant or other 
saliva substitutes) two weeks before and during the trial 
period, but were permitted to take frequent sips of water for 
their comfort. They were also allowed to use other mouth 
care products (for treating oral disease) which did not affect 
xerostomia symptoms if indicated (e.g., topical analgesics, 
topical antiseptics, and antifungals). They were also advised 
to stop using the study products if any problems.  
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Treatment Protocol 
Fifty patients were blinded and randomly assigned (1:1) 
to receive either the commercially available gel formulation 
of CMC saliva substitutes (GC Dry Mouth Gel®, CMC group), 
or the gel formula of  saliva substitute containing lysozyme, 
lactoferrin, and lactoperioxidase (Biotene®, ENZ group) for 
home application for 2 weeks. The containers of the saliva 
substitutes were weighed prior to dispensing and imme-
diately after the patients returned them to the examiner at 
the end of the treatment period.   
Each patient was instructed to apply a sufficient amount 
of the saliva substitute on their tongue, gum, and any soft 
tissue with their fingertip, cotton swab or with their own 
tongue for at least 4 times a day (before and after meals, 
and at bedtime) and re-applied between meals as needed 
whenever they had a dry mouth.    
 
Xerostomia-related Quality of Life Questionnaire  
Items of our Xerostomia-related Quality of Life Scale 
(XeQoLS) were modified from xerostomia questionnaires of 
Shahdad et al 11, Meirovitz et al15, and Henson et al.1 The 
XeQoLS was translated into Thai language by a dentist and 
tested in 20 patients before it was adjusted and approved by 
another two senior dentists. Four major domains of the 
XeQoLS included physical functioning, personal/psycho-
logical functioning, social functioning and pain/discomfort. In 
addition, the XeQoLS included other aspects of clinical 
acceptance (Table 2).  
The XeQoLS had two parts. Part 1 contained 8 questions 
with continuous response score derived from a 100 mm. 
visual analogue scale (VAS) where positive response was 
placed on the left and negative response on the right (for 
example, 0 = not dry at all and 100 = the worst imaginable 
dryness). These 8 questions were asked before and after 
treatment (questions shown in Table 2). The main VAS 
question for xerostomia severity asked “How dry is your 
mouth?”  Part 2 contained Yes/No type questions where 12 
questions were applicable for pre-treatment, and their 
accompanying questions for post-treatment. For example, 
“Do you have difficulty chewing because of your dry mouth?” 
was accompanied with “Did the product make chewing 
easier?” In addition, there were 4 additional questions 
applicable only for post-treatment (Table 2).  
Internal consistency of the XeQoLS’s VAS scoring 
questions dichotomous scoring questions was acceptable 
with Cronbach alpha of 0.84 and KR-20 coefficient of 0.76, 
respectively. All participating patients completed the pre-
treatment questionnaires before randomization (day 0) and 
the post-treatment questionnaire at the end of treatment 
period (day 14). The same dentist read the XeQoLS to each 
patient in Thai language. All patients completed the XeQoLS 
by themselves without any help or interruption.   
 
Outcome measures  
Xerostomia severity level and xerostomia-related quality 
of life based on 100 mm. VAS, before and after 14 days of 
treatment were assessed in each group. At the end of the 2-
week treatment period, patients with a decrease of 10 – 24 
mm. score from baseline were classified as “having a 
response”; while those with a decrease of ≥ 25 mm. from 
baseline as “having a major improvement” in their symptoms. 
However, patients with a decrease of <10 mm. from baseline 
were classified as non-responders.12,13  
 
Statistic Analysis  
For 1-β = 0.8, and α =0.05, a sample size of 17 was 
required to demonstrate an effect size of 0.5. Allowing for a 
dropout rate of approximately 10%, at least 21 patients 
should be recruited into each group of this study.  
Data were analyzed using SPSS for Windows version 
17.0. Means and standard deviations of continuous variables 
were calculated. Patient and tumor characteristics between 
two groups were compared using t-test or chi-square test 
when applicable. Analysis of covariance (ANCOVA) was 
used to compare mean response differences between 
groups after accounting for pre-existing differences at 
baseline. Chi-square statistics were calculated to assess 
categorical parameters between groups. A P-value of less 
than 0.05 was considered significant.    
      
Results 
Fifty patients, 25 in each group, were enrolled into this 
study. All patients reported grade 2 - 3 xerostomia after 
receiving conventional RT or bilateral IMRT for HNC with 
field of irradiation encompassing the major and minor 
salivary glands. The radiation dose range was about 66 – 70 
Gy. Patients who received bilateral IMRT had completed 
their RT within 12 months before enrollment. Patient and 
tumor characteristics were comparable between groups 
(Table 1).   
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Table 1 Patient and tumor characteristics.   
 CMC group 
(n = 25) 
ENZ group 
(n = 25) 
Age (years)   
Mean ± SD 48.6 ± 10.27 50.84 ± 11.88 
Median 51 50 
Gender, n (%)   
Men 12 (48) 15 (60) 
Women 13 (52) 10 (40) 
Primary cancer site, n (%)   
Nasopharynx 19 (76) 19 (76) 
Base of tongue 0 1 (4) 
Floor of mouth 1 (4) 2 (8) 
Maxillary sinus 1 (4) 0 
Parotid 2 (8) 1 (4) 
Tonsil 2 (8) 1 (4) 
Floor of nose 0 1 (4) 
Clinical stage of cancer, n (%)   
I 4 (16) 2 (8) 
II 4 (16) 7 (28) 
III 8 (32) 11 (44) 
IV 9 (36) 5 (20) 
Radiation technique, n (%)   
Conventional RT  13 (52)            11 (44) 
IMRT 11 (44) 14 (56) 
3-D CRT 1 (4) 0 
Duration after radiation (months)   
Mean ± SD 32.76 ± 46.92 31.63 ± 41.83 
Median 14.40 12.72 
Concomitant chemotherapy (%) 96 96 
Note: IMRT = intensity modulated radiation therapy; 3-D CRT = three dimensional conformal radiotherapy.  
 No significant differences between groups ( t-test for mean and chi-square test for frequency.   
 
Most patients found that both saliva substitute products 
were easy to use. The mean quantity of saliva substitute 
usage in CMC and ENZ groups were 30.44 ± 15.95 g and 
39.40 ± 22.93 g, respectively (P-value = 0.23, t-test).  
At baseline (day 0), mean VAS scores of the main 
xerostomia severity (How dry is your mouth?) in CMC and 
ENZ groups were 81.2 and 85.6 mm, respectively. At day 
14, such xerostomia severity was alleviated in both groups 
(mean VAS scores of 50.1 and 52.1 mm, respectively) with 
no statistical significance (P-value = 0.87). At day 14, there 
were no differences between groups in all other XeQoLS 
questions and clinical aspects (Table 2).  
The proportion of patients who responded to the 
treatment and those who had a major improvement from 
baseline in various domains of XeQoLs are shown in Table 
3. In both groups, 8 patients (32%) reported a response to 
the treatment as their severity of xerostomia score improved 
(i.e., an increase of ≥ 10 mm.) from their baseline and 17 
(68%) patients reported a major improvement (i.e., ≥ 25 
mm.) of their severity of xerostomia score.  
No statistically significant difference in all variables of the 
four major domains and other aspects of clinical acceptance 
was found between groups. In addition, no adverse event 
related to any studied products was reported. 
 
 
Table 2 Xerostomia related quality of life and other clinical acceptance between the two groups at day 0 and 14 of 
treatment.   
 
Parameters  
Response by groups 
P-value CMC group 
(n = 25) 
ENZ group  
 (n = 25) 
1. Physical functioning  
VAS score, mean (SD) 
1.1 Do you have difficulty chewing because of your dry mouth? 
      Before treatment  
      After treatment  
 
 
 
84.0 (10.11) 
57.6 (21.73) 
 
 
 
80.9 (15.58) 
55.4 (22.04) 
 
 
 
< 0.001* 
0.96† 
1.2 Do you have difficulty swallowing because of your dry mouth?   
      Before treatment  
      After treatment   
 
84.7 (17.16) 
61.5 (21.75) 
 
78.6 (15.50) 
56.1 (22.17) 
 
< 0.001* 
0.81† 
1.3 Is speech difficult because of your dry mouth?   
      Before treatment   
      After treatment   
 
69.2 (21.09) 
45.8 (20.98) 
 
56.3 (25.77) 
38.9 (22.48) 
 
< 0.001* 
0.60† 
1.4 Is taste affected by your dry mouth?   
       Before treatment 
       After treatment 
 
78.0 (21.34) 
61.8 (22.61) 
 
65.6 (26.26) 
51.1 (23.70) 
 
< 0.001* 
0.80† 
   Contd. 
Note: The scale was set up with positive responses on the left and negative responses on the right (e.g., 0 = not dry at all, 100 = the worst imaginable dryness).  
  * t-test; † ANCOVA adjusting for baseline (before treatment) difference.  
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Table 2 (contd.) Xerostomia related quality of life and other clinical acceptance between the two groups at day 0 and 
14 of treatment.    
Parameters 
Response by groups 
P-value CMC group 
(n = 25) 
ENZ group 
(n = 25) 
Dichotomous responses variables, n (%)    
1.5 (before treatment) Do you have difficulty chewing because of your dry mouth?  
      (after treatment) Did the product make chewing easier?   
22 (88%) 
18 (72%) 
23 (92%) 
18 (72%) 
1.00‡ 
1.00‡ 
1.6 (before treatment) Do you have difficulty swallowing because of your dry mouth?  
     (after treatment) Did the product make swallowing easier?  
25 (100%) 
17 (68%) 
25 (100%) 
18 (72%) 
1.00‡ 
1.00‡ 
1.7 (before treatment) Do you have speech difficult because of your dry mouth?  
     (after treatment) Did the product make talking easier?  
21 (84%) 
21 (84%) 
17 (68%) 
18 (72%) 
0.32‡ 
0.50‡ 
1.8 (before treatment) Is taste affected by your dry mouth?  
     (after treatment) Did the product improve your sensation of taste?  
24 (96%) 
16 (64%) 
21 (84%) 
13 (52%) 
0.35‡ 
0.39‡ 
2. Pain/Discomfort 
VAS score, mean (SD)  
   
2.1 How dry is your mouth?  
     Before treatment  
     After treatment 
 
81.2 (8.84) 
50.1 (17.80) 
 
85.6 (11.30) 
52.1 (16.41) 
 
< 0.01* 
0.87† 
2.2 Do you have a burning sensation in your mouth?        
     Before treatment  
     After treatment 
 
64.0 (34.95) 
47.8 (32.94) 
 
66.8 (34.32) 
56.5 (32.41) 
 
< 0.001* 
0.14† 
Dichotomous responses variables, n (%)    
2.3 (before treatment) Do you suffer from a dry mouth?   
     (after treatment) Did the product make your dry mouth better?  
25 (100%) 
25 (100%) 
25 (100%) 
25 (100%) 
1.00‡ 
1.00‡ 
2.4 (before treatment) Do you have a burning sensation in your mouth?   
     (after treatment) If you had a burning mouth, did the product improve the burning sensation?  
18 (72%) 
9 (36%) 
19 (76%) 
11 (44%) 
0.59‡ 
1.00‡ 
2.5 (before treatment) Do you suffer from a dry mouth in the daytime?  
     (after treatment) Was the product most useful in the daytime?   
23 (92%) 
22 (88%) 
23 (92%) 
22 (88%) 
1.00‡ 
1.00‡ 
3. Personal / psychological functioning 
Dichotomous responses variables, n (%) 
   
3.1 (before treatment) Do you visit people less frequently because of your dry mouth?  
      (after treatment) Did you visit people more than you used to?   
13 (52%) 
12 (48%) 
13 (52%) 
8 (32%) 
1.00‡ 
0.39‡ 
4. Social functioning    
Dichotomous responses variables, n (%)    
4.1 (before treatment) Do you avoid speaking to people because of your dry mouth?   
      (after treatment) Did you speak to people more than you used to? (at day 14)   
14 (56%) 
15 (60%) 
10 (40%) 
13 (52%) 
0.40‡ 
0.78‡ 
4.2 (before treatment) Do you stay at home more because of your dry mouth?   
     (after treatment) Do you get out the house more than you used to?   
14 (56%) 
9 (36%) 
12 (48%) 
11 (44%) 
0.78‡ 
0.77‡ 
5. Other clinical acceptance 
VAS score, mean (SD) 
 
 
 
 
 
 
5.1 Do you have difficulty with sleeping caused by your dry mouth? 
     Before treatment   
     After treatment  
 
69.56 (25.58) 
41.52 (25.36) 
 
57.16 (26.71) 
39.12 (23.82) 
 
< 0.001* 
0.41† 
5.2 How often do you sipping liquids for oral comfort when not eating? 
      Before treatment   
      After treatment  
 
71.08 (23.08) 
45.12 (20.13) 
 
69.36 (23.19) 
46.92 (20.07) 
 
< 0.001* 
0.43† 
Dichotomous responses variables, n (%)    
5.3 (before treatment) Do you suffer from a dry mouth in the night time?   
     (after treatment) Did the product stop you waking in the night?  
19 (76%) 
17 (68%) 
20 (80%) 
16 (64%) 
1.00‡ 
1.00‡ 
5.4 (before treatment) If you wear dentures, does your dry mouth affect the retention of the dentures?  
      (after treatment) If you wear dentures, did the product help with the retention of the dentures?  
3 of 7 (42.9%) 
2 of 7 (28.6%) 
3 of 6 (50%) 
1 of 6 (16.7%) 
1.00‡ 
1.00‡ 
5.5 (after treatment) Did the product improve your quality of life?   22 (88%) 22 (88%) 1.00‡ 
5.6 (after treatment) Was the product easy to use?   22 (88%) 24 (96%) 0.60‡ 
5.7 (after treatment) Did you feel better when using this product?  22 (88%) 23 (92%) 1.00‡ 
5.8 (after treatment) Would you like to continue using this product?  20 (80%) 23 (92%) 0.42‡ 
Note: The scale was set up with positive responses on the left and negative responses on the right (e.g., 0 = not dry at all, 100 = the worst imaginable dryness).  
        * t-test; † ANCOVA adjusting for baseline (before treatment) difference; ‡ chi-squared test.   
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Table 3 Number of patients who had a response (a VAS score decrease of 10 - 24 mm.) and 
major improvement (a VAS score decrease of ≥ 25 mm.) from baseline.  
Parameters 
Response by groups 
P-value* CMC group 
(n = 25) 
ENZ group 
(n = 25) 
1. Physical functioning 
 1.1 Do you have difficulty chewing because of your dry mouth? 
   
0.69 
number of patients with a VAS score decrease of <10 mm. 3 (12%) 4 (16%)  
number of patients with a response  9 (36%) 11 (44%)  
number of patients with a major improvement    13 (52%) 10 (40%)  
1.2 Do you have difficulty swallowing because of your dry mouth?   0.74 
number of patients with a VAS score decrease of <10 mm. 4 (16%) 6 (24%)  
number of patients with a response  11 (44%) 9 (36%)  
number of patients with a major improvement    10 (40%) 10 (40%)  
1.3 Is speech difficult because of your dry mouth?   0.10 
number of patients with a VAS score decrease of <10 mm. 3 (12%) 5 (20%)  
number of patients with a response  11 (44%) 16 (64%)  
number of patients with a major improvement    11 (44%) 4 (16%)  
1.4 Is taste affected by your dry mouth?   0.48 
number of patients with a VAS score decrease of <10 mm. 6 (24%) 10 (40%)  
number of patients with a response  13 (52%) 10 (40%)  
number of patients with a major improvement    6 (24%) 5 (20%)  
2. Pain/Discomfort 
2.1 How dry is your mouth? 
   
1.00 
number of patients with a VAS score decrease of <10 mm. 0 0  
number of patients with a response  8 (32%) 8 (32%)  
number of patients with a major improvement    17 (68%) 17 (68%)  
2.2 Do you have a burning sensation in your mouth?   0.47 
number of patients with a VAS score decrease of <10 mm. 9 (36%) 11 (44%)  
number of patients with a response  11 (44%) 12 (48%)  
number of patients with a major improvement    5 (20%) 2 (8%)  
3. Other clinical acceptance 
3.1 Do you have difficulty with sleeping caused by your dry mouth? 
   
0.33 
 number of patients with a VAS score decrease of <10 mm. 5 (20%) 6 (24%)  
number of patients with a response  8 (32%) 12 (48%)  
number of patients with a major improvement    12 (48%) 7 (28%)  
3.2 How often do you sip liquid for oral comfort when not eating?   0.31 
number of patients with a VAS score decrease of <10 mm. 2 (8%) 2 (8%)  
number of patients with a response  12 (48%) 17 (68%)  
number of patients with a major improvement    11 (44%) 6 (24%)  
Note: * Chi-squared statistics.  
 
Discussions and Conclusion 
In this randomized study, we examined the efficacy of 
CMC-based and enzyme containing saliva substitutes on 
QoL. We used the Xerostomia-related Quality of Life Scale 
(XeQoLS) which were questions on xerostomia severity we 
had modified from various studies.1,11,15 The use of 
xerostomia severity questionnaire in our study was in 
accordance with previous studies where they reported the 
effects of saliva substitute evaluated by the xerostomia 
questionnaire (XQ).5-7,11-13 Our study was successful in 
determining subjective measure of oral dryness and 
evaluating effects of treatments in patients with xerostomia. 
After 2 weeks of treatment, we found no statistically 
significant difference between groups, in each issue in all 
four major domains of XeQoLS and other aspects of clinical 
acceptance that related to QoL.  
Even though no differences between groups, each of the 
two saliva substitutes appeared to offer a major improvement 
in xerostomia severity (representing discomfort issue) and 
difficulty chewing (representing physical functioning). The 
results further showed that both products improved physical 
functioning problems which included difficulty chewing (major 
improvement) and difficulty swallowing; however, patients still 
needed to drink while eating. Patients with eating problems 
which limited their nutritional intake and risked jeopardizing 
the continuation of therapeutic radiation and chemotherapy, 
found that saliva substitutes would be an alternative therapy 
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to improve their ability to eat normally. Also both products 
were able to help patients with speech difficulty (representing 
physical functioning). Saliva substitutes can benefit patients 
with simple activities such as telephone conversation or 
participation in meetings, and patients who need extensive 
speaking in their jobs (e.g., teachers, sale persons, and 
priests).7,12 Therefore, this means the improvement of the 
social and personal functioning aspects of quality of life.  
Both saliva substitutes also alleviated problem with taste 
alteration (representing physical functioning). Such improve-
ment was crucial since impaired taste is associated with 
weight loss through reduced appetite and altered food intake 
patterns, further profoundly reducing patients' QoL.14 While 
Temmel et al15 reported that these "simple" lubricants 
containing CMC have little or no effect on whole-mouth 
gustatory function, our study suggested that in patients 
whose taste alteration problem affects their nutritional intake, 
both saliva substitutes seemed to be preferable.  
Regarding improvement of burning sensation (intolerance 
to spicy foods, representing pain/discomfort issue), both 
saliva substitutes helped patients not to suffer from eating 
especially spicy foods. Similarly, both products improved 
quality of sleep in a majority of patients, especially in CMC 
groups where 48% showed a major improvement. This could 
be partly due to the effect duration of both saliva substitutes 
was long enough to reduce the need to awaken to moisten 
their mouth or to pass urine (as a result of decreased need 
for fluid ingestion).12 Some patients gained weight and felt 
healthier from the improvement in nocturnal sleep pattern 
(data not shown). A large number of patients in CMC group 
(44%) also had a major improvement regarding frequency of 
sipping water.  
Enduring effect of saliva substitute may not be a sole 
reason for continuing use as Momm et al7 reported that the 
reason could also be patients’ appreciation including the 
product’s good taste and easy usage. Since patients may 
have very different opinions about taste of the product, the 
best treatment of xerostomia seems to highly depend on 
personal preference. Every patient should therefore be 
encouraged to test different artificial saliva products to find 
the best individual way to cope with their xerostomia. Cost of 
different saliva substitutes should also be considered when 
assisting individual patients to select a preferred agent.   
Among patients wearing denture, both products can 
improve the retention of the denture in 28.6% of patients in 
CMC group and 16.7% in ENZ group. This is probably 
because the formulation of both products is gel which usually 
can improve denture retention and lubrication. However, this 
benefit is yet questionable since only few patients with 
denture problems were included in the study.  
Four methodological issues in our study should be 
addressed. First, with recurring outcome characteristics, a 
relatively short duration of symptom alleviation, and a 
relatively small sample size, a cross-over study design could 
have lessened inter-patient variability between the two 
groups. This however should not be a significant design 
drawback since the characteristics of our patients were 
comparable between groups in all aspects.  
The second issue is that the correlations between 
subjective patient-reported scores and objective measures of 
salivary functions were not determined in this study. Our 
outcome measures however are still valid and reliable since 
there has been an advocate for validity of patient self-report 
of symptom severity during xerostomia treatment. Meirovitz 
and colleagues16 reported that patient self-reporting, rather 
than physician-assessed scores should be the main end 
point in evaluating xerostomia. Patient self-reported 
xerostomia related to QoL was consistently significant 
determinant of treatment intervention throughout post-RT 
study period. XQ was used in studies evaluating the efficacy 
of saliva substitutes.5-7,11-13  
Third, the extent of radiation-induced salivary dysfunction 
can be influenced by several factors, for instance, radiation 
dose, the pre-treatment function of salivary gland, radiation 
technique, the extent of radiation field (especially the volume 
of the salivary gland receiving full-dose RT). In the patient-
self reported study, the inclusion criteria are very important. 
The homogeneous tumor sites and stage, operation 
performed (radiation technique and dose, and surgery) 
should be similar between study groups. Jabbari19 reviewed 
that after initial post xerostomia, QoL was improved overtime 
after IMRT but not after standard RT. Chronic xerostomia is 
still a considerable problem for QoL in HNC patients after 
RT. QoL was influenced by the time since RT.4 In this study, 
we identified time interval since RT completion so that we 
could include xerostomic patients as much homogeneous as 
possible.  
The fourth methodological issue is that no placebo-
control group was included in our study and it was accepted 
that the improvement could be partly due to a placebo effect. 
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It is also not clear that to what extent QoL scores are 
susceptible to a placebo effect. However, CMC saliva 
substitute could be considered a controller as in the study of 
Epstein et al (1999).5  
In conclusion, we observed no significant difference in all 
four major domains of xerostomia related quality of life and 
other aspects of clinical acceptance between CMC based 
saliva substitute and enzyme-containing saliva substitute 
usage. Comparing between groups, proportions of patients 
who reported a response and a major improvement from 
baseline scores on xerostomia were not different in physical 
functioning and pain/discomfort domains of xerostomia-
related quality of life, and other aspects of clinical 
acceptance.  
 
Acknowledgements  
This study was supported by grants from Chula Quality 
Improvement Fund, King Chulalongkorn Memorial Hospital.  
 
References 
1. Henson BS, Inglehart MR, Eisbrusch A, Ship JA. Preserved salivary 
output and xerostomia –related quality of life in head and neck cancer 
patients receiving parotid-sparing radiotherapy. Oral Oncol 2001;37(1): 
84-93.  
2. Ship JA, Hu K. Radiotherapy-induced salivary dysfunction. Sem Oncol 
2004;(suppl 18):29-36.  
3. Dirix P, Nuyts S, Van den Boqaert N. Radiation-induced xerostomia in 
patients with head and neck cancer: a literature review. Cancer 2006; 
107(11):2525-2534.  
4. Dirix P, Nuyts S, Poorten V, Delaere P, van den Boqaert W. The 
influence of xerostomia after radiotherapy on quality of life. Support 
Care Cancer 2008;16(2):171-179.  
5. Epstein JB, Emerton S, Le ND, Stevenson-Moore P. A double-blind 
cross-over trial of Oral Balance gel and Biotene® toothpaste versus 
placebo in patients with xerostomia following radiation therapy. Oral 
Oncol 1999;35(2):132-137.  
6. Oh DJ, Lee JY, Kim YK, Kho HS. Effects of carboxymethylcellulose 
(CMC)-based artificial saliva in patients with xerostomia. Int J Oral 
Maxillofac Surg 2008;37:1027-1031.  
7. Momm F, Voleqova-Neher NJ, Schulte-Mönting J, Guttenberger R. 
Different saliva substitutes for treatment of xerostomia following 
radiotherapy: a prospective crossover study. Strahlenther Onkol 2005; 
181(4):231-236.  
8. Suguira Y, Soga Y, Tanimoto I, et al. Antimicrobial effects of the saliva 
substitutes, Oralbalance®, against microorganism from oral mucosa in 
the hematopoietic cell transplantation period. Support Care Cancer 
2008;16(4):421-424.  
9. Suguira Y, Soga Y, Yamabe K, et al. Total bacterial counts on oral 
mucosa after using a commercial saliva substitute in patients under-
going hematopoietic cell transplantation. Support Care Cancer 2010; 
18(3):395-398.  
10. Nagy K, Urban E, Fazekas O, Thurzo L, Nagy E. Controlled study of 
lactoperioxidase gel on oral flora and saliva in irradiated patients with 
oral cancer. J  Craniofac Surg 2007;18(5):1157-1164.  
11. Shahdad SA, Taylor C, Barclay SC, Steen IN, Preshaw PM. A double-
blind cross-over study of Biotene Oralbalance and Bioxtra systems as 
salivary substitutes in patients with post-radiotherapy xerostomia. Eur J 
Cancer Care 2005;14(4):319-326.  
12. Warde P, Kroll B, O’Sullivan B, et al. A phase II study of Biotene in the 
treatment of postradiation xerostomia in patients with head and neck 
cancer. Support Care Cancer 2000;8(3): 203-208.  
13. Lin A, Kim HM, Terrell JE, Dawson LA, Ship JA, Eisbruch A. Quality of 
life after parotid-sparing IMRT for head-and-neck cancer: a prospective 
longitudinal study. Int J Radiat Oncol Biol Phys 2003;57(1):61-70.  
14. Hahnel S, Behr M, Handel G, Bürgers R. Saliva substitutes for the 
treatment of radiation-induced xerostomia--a review. Support Care 
Cancer 2009;17(11):1331-1343.  
15. Meirovitz A, Murdoch-Kinch CA, Schipper M, Pan C, Eisbruch A. 
Grading xerostomia by physicians or by patients after intensity-
modulated radiotherapy of head-and-neck cancer. Int J Radiat Oncol 
Biol Phys 2006;66(2):445-453.  
16. Dirix P, Nuyts S, Vander Poorten V, Dalaere P, Van den Boquaert W. 
Efficacy of the Bioxtra dry mouth care system in the treatment of 
radiotherapy-induced xerostomia. Support Care Cancer 2007;15(12): 
1429-1436.  
17. Ruo Reddar MG, Allis S. Radiotherapy-induced taste impairment. 
Cancer Treat Rev 2006;32(7):541-547.   
18. Temmel AF, Quint C, Schickinger-Fischer B, Hummel T. Taste function 
in xerostomia before and after treatment with saliva substitute 
containing carboxymethylcellulose. J Otolaryngol 2005;34(2):116-120.   
19. Jabbari S, Kim HM, Feng M, at al. Matched case-control study of 
quality of life and xerostomia after intensity-modulated radiotherapy or 
standard radiotherapy for head-and-neck cancer: initial report. Int J 
Radiat Oncol Biol Phys 2005;63(3):725-731.   
 
 
 Editorial note 
Manuscript received in original form on March 4, 2011;  
accepted in final form on September 27, 2011 
